Restore Vision & Clarity Ocuphire Corporate Presentation August 2023 2 This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements i

Restore Vision & Clarity Ocuphire Corporate Presentation August 2023

2 This presentation contains "forward-looking statements" within the meaning of

the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the success and timing of planned regulatory filings and approvals, pre-commercial activities, commercialization

strategy and timelines, business strategy, product labels, cash runway, scalability, future clinical trials in presbyopia (P), dim light/night vision disturbance (DLD) and diabetic retinopathy (DR) / diabetic macular edema (DME), including

the potential for Nyxol to be a "best in class" presbyopia drop, and timing of planned future clinical trials for APX3330, APX2009 and APX2014, timing and occurrence of an End-of-Phase 2 meeting with the FDA, the potential of a Phase 3

registration path for APX3330, the success and timing of planned regulatory filings, business strategy, cash runway, scalability, the potential for APX3330 to be the most advanced and the first line of therapy for DR patients, and the

potential market opportunity for the slowing of DR progression. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results

and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success, costs, and timing of regulatory

submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource

requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic

developments, (vii) changes in market opportunities, (viii) risks that the partnership with Viatris may not facilitate the commercialization or market acceptance of Ocuphire's product candidates; (ix) the success and timing of

commercialization of any of Ocuphire's product candidates, including the scalability of Ocuphire's product candidates and (x) the maintenance of Ocuphire's intellectual property rights. The foregoing review of important factors that could

cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been

and may be filed by the Company from time to time with the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to

reflect events that occur or circumstances that exist after the date on which they were made. The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained in or

incorporated by reference into this presentation. Nothing contained in or incorporated by reference into this presentation is, or shall be relied upon as, a promise or representation by the Company as to the past or future. The Company

assumes no responsibility for the accuracy or completeness of any such information. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our

industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The trademarks included herein are the property of the owners thereof and are used for reference purposes

only. Such use should not be construed as an endorsement of such products. Disclosures and Forward-Looking Statements

3 Corporate Highlights Strong Financial Position to Advance

APX3330 Late-Stage Clinical Candidates for Retinal Diseases Represent Multi-Billion Dollar Opportunity APX3330: Paradigm Changing, Non-invasive, Safe Oral Tablet for millions of NPDR patients that are currently left untreated Ref-1, a

novel, dual target (angiogenesis and inflammation) for retinal diseases ZETA-1 Phase 2 demonstrated slowing progression of Diabetic Retinopathy (DR) with statistically significant efficacy on potential Phase 3 registration endpoint Nyxol:

Eyedrops for refractive disorders Global License Agreement with Viatris to Fund all Development and Commercialization for Nyxol Indications: Reversal of Mydriasis (RM)- PDUFA Date on September 28, 2023. Approval would trigger $10M

milestone Presbyopia- currently in Phase 3 Dim Light Disturbances- currently in Phase 3

4 Ocuphire Pipeline Product Candidate Indication Pre-clinical Phase

1 Phase 2 Phase 3 Regulatory Approval Upcoming Milestones APX3330 Oral Pill Diabetic Retinopathy (DR) EOP2 Meeting EOP2 Mtg Q4 2023 APX3330 Local Delivery Retina Select retinal drug delivery technology APX2009 and

APX2014 Local Delivery Retina Select retinal drug delivery technology Nyxol Eyedrops Reversal of Mydriasis (RM) Partnered with Viatris PDUFA Date Sep 28, 2023 Presbyopia (P) VEGA-2 Phase 3 Topline Data Q4 2023 Dim Light or Night

Vision Disturbances (DLD) LYNX-2 2nd Phase 3 trial (n=150+)

5 Diabetic Retinopathy Market and Unmet Need

6 Diabetic Eye Disease is Common Cause of Blindness Diabetes and Diabetic

(DR) https://webeye.ophth.uiowa.edu/eyeforum/tutorials/diabetic-retinopathy-med-students/Classification.htm https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/symptoms-causes/syc-20353011 https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/symptoms-causes/syc-20351193 Diabetes

Mellitus is a group of diseases characterized by high blood glucose levels. Diabetes results from defects in the body's ability to produce and/or use insulin Diabetic retinopathy (DR) occurs when fluctuations or instability in blood glucose

levels damages blood vessels in the retina Type 1 diabetes (T1D): The body produces very little or no insulin, which means that patients need daily insulin injections to maintain blood glucose levels Type 2 diabetes (T2D): The most common

form of diabetes - either the body does not produce enough insulin, or resists insulin Normal Retina Diabetic Retina Two Types of DR Non-Proliferative Diabetic Retinopathy (NPDR) - most common form of DR - early stages of edema and

exudates, blurred central vision Proliferative Diabetic Retinopathy (PDR) - later stage of DR, marked by abnormal blood vessels and scar tissue on retina Diabetic Macular Edema (DME) can occur at any stage of DR

7 American Diabetes Association; International Diabetes Federation; Healthline;

*Ocuphire internal analysis and assumptions; Das UN. DME, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci. 2016;12(5):1142-1157. doi:10.5114/aoms.2016.61918 Patient survey adapted from Lions

International Foundation and International Diabetes Foundation-Europe; Meltzer 2000 Guidehouse Triangulation of Global Data, Market Scope and Investor Forecasts (2020) AMD = Age-Related Macular Degeneration; DME = Diabetic Macular Edema ;

BRVO = Branch Retinal Vein Occlusion National Center for Chronic Disease Prevention & Health Promotion. Health & economic costs of chronic diseases. Atlanta (GA): Centers for Disease Control & Prevention, US Department of Health

and Human Services; 2018 Four-Year Visual Outcomes in a Randomized Trial of Intravitreous Aflibercept for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)." JAMA. February 7, 2023 Diabetic Retinopathy At a

Glance Current Treatment Landscape Demonstrates Need for Non Invasive Therapies The number of people with DR expected to increase more than 14M by 2050 There are ~8M adults in the U.S. with NPDR DR is the leading cause of blindness among

working- age adults with the median age of onset at 45 - 50 years Majority of moderate to severe patients with DR are not treated with anti-VEGF due to injection burden and no benefit to visual acuity Prevention of Progression is favored by

payors in chronic disease such as diabetes which is the leading cost driver Physicians have no non-invasive options for NPDR with current standard being wait-and-monitor

8 American Diabetes Association; International Diabetes Federation; Healthline;

*Ocuphire internal analysis and assumptions; Spherix Global Insights Patient survey adapted from Lions International Foundation and International Diabetes Foundation-Europe; Meltzer 2000 Estimates are provided by the National Eye Institute,

FactSheet, Global Data, and Research and Markets. Estimated values are rounded. Estimated prevalence in the U.S.; DME- Diabetic Macular Edema; Age-related Macular Degeneration; Geographic Atrophy; Retinal Vein Occlusion U.S Diabetic

Retinopathy Market 10M Diabetic Retinopathy (DR) 8M NPDR Patients US Market Opportunity Target Patient Population ~$6B+ 27% 27% 24% 22% Proliferative diabetic retinopathy (PDR) Severe non-proliferative diabetic

retinopathy (NPDR) Moderate non-proliferative diabetic retinopathy (NPDR) Mild non-proliferative diabetic retinopathy (NPDR) 78% NPDR Non-Proliferative DR Proliferative DR Majority of the DR patients are NPDR Severity Target

Population for APX3330 Real-World Chart Review of DR Patients in US % of Patients 34 Million Diabetics in US Types of DR

9 Spherix Global Insights: DR Market DYNAMIX October 2022 Early treatment

diabetic retinopathy study research group. ophthalmology. 1991;98(5 suppl):823-33. Diabetes control and complications trial research group. N Engl J Med. 1993;329(14):997-86. Fathy C, Patel S, Sternberg P Jr, Kohanim S. Disparities in

adherence to screening guidelines for diabetic retinopathy in the United States: a comprehensive review and guide for future directions. Semin Ophthalmol. 2016;31(4):364-377. doi: 10.3109/08820538.2016.1154170 Progression Based on DR

Severity NPDR Patients are Rarely Treated with anti-VEGF Intravitreal Injections; Non-Invasive, Early Intervention is an Unmet Need 0% 20% 40% 60% 80% 100% Mild NPDR (35) Moderate NPDR (43) Moderately Severe NPDR (47) Severe NPDR

(53) 5% 12% 26% 52% 14% 30% 48% 71% 25% 40% 66% 80% 1 Year Follow-up 5 Year Follow-up 3 Year Follow-up Percentage of Eyes that Worsen to PDR Regardless of severity, all eyes worsen over time

10 10% 20% 30% 40% 50% 60% 70% International

US 59.5% 60.5% 17.0% 24.9% 7.7% 7.8% 4.9% 3.1% 10.9% 3.7% ASRS 2021 Preferences and Trends (PAT) Survey ASRS PAT Survey: Majority of Physicians Use a "Wait and Monitor" Approach for DR NPDR Patients Are Not Treated Proactively

and Anti-VEGF Use is Limited How do physicians treat patients with severe NPDR without DME? Closely monitor retinopathy and encourage systemic glycemic control Consider anti-VEGF in some patients with poor glycemic control and/or other

risks Consider anti-VEGF in some patients with good glycemic control and compliance Consider anti-VEGF therapy in all or most patients Other 0%

11 Diabetic Retinopathy Treatment Landscape

12 Landscape of Non-Invasive Therapies for Diabetic Retinopathy Ocuphire's

APX3330 is the Most Advanced and The Only Dual Mechanism Oral Drug Candidate Company websites and www.clinicaltrials.gov (as of July 31, 2023) Completed Ongoing Discontinued Company Drug Target/MOA Indication Route of

Administration Phase 1 Phase 2 Phase 3 Primary Endpoint/ Secondary Endpoints APX3330 Ref-1 inhibitor (Anti-VEGF and Anti-inflammatory) DR Oral 2022 2020: 2-step DRSS @wk24 RG7774 CB2 receptor

(cannabinoid) DR Oral 2020: 2-step DRSS @wk36 BAY1101042 Guanylate Cyclase activator DR Oral 2021: 2-step DRSS @wk24 OPL-0401 ROCK 1/2 inhibitor DR Oral 2021: 2-step DRSS @wk24 OTT166 Integrin

inhibitor DR Eyedrop 2022: 2-step DRSS @wk24 Note: Two Tyrosine Kinase and a Plasma Kallikrein Inhibitors failed as orals in Phase 2 due to dose limiting adverse events (e.g., liver and cardiovascular) APX3330

Differentiation Mechanism: Dual MOA targeting validated retinal pathways of angiogenesis and inflammation Human exposure: >10,000 subject days of systemic exposure in humans at 600mg/day dose Favorable safety and tolerability

13 Landscape of Invasive Therapies (IVT/Suprachoroidal) for Diabetic

Retinopathy Eylea /Lucentis Approved, But Not Used in Patients with NPDR; Rarely Used in Mild PDR Company Drug Target/MOA Route of Administration Phase 1 Phase 2 Phase 3 Commercial Eylea (aflibercept) VEGF-A/B;

PIGF Intravitreal *1 Lucentis (ranibizumab) VEGF-A Intravitreal 2 KSI-301 (Tarcocimab) VEGF Intravitreal N/A EYP-1901 Voloronib (TKI) Intravitreal BI 764524 Anti-Sema3A Ischemia

modulator Intravitreal OTX-TKI Axitinib* (TKI) Intravitreal RGX-314 AAV8-VEGF Suprachoroidal (Gene Therapy) Completed Ongoing X Discontinued *Trials to Support Approval 1 Panorama Clinical Trial 2 Protocol I

& T and Rise & Ride * Failed as oral/systemic treatments in retina due to dose limiting toxicity Company websites and www.clinicaltrials.gov (as of July 31, 2023) Eylea is trademark of Regeneron and Lucentis is trademark of

14 APX3330 Background

15 Logsdon et al (2018), Li et al (2014). APX3330 History and Ref-1 Inhibition

Mechanism Ref-1 Involved in Key Pathways that Contribute to Diabetic Retinopathy and DME Mechanism of Action - Ref-1 Inhibition Hypoxia Ref-1 HIF-1 VEGF (Signaling Cascade) Inflammation Ref-1 NF- B Other Growth Factors (Signaling

Cascade) TNF- Chemokines Neovascularization Lucentis EYLEA Anti-VEGF Steroids APX3330 Ref-1 (reduction-oxidation effector factor-1), a novel target for retinal diseases, is a transcription factor regulator of angiogenesis (VEGF)

and inflammation (NFkB) Unique dual MOA decreases abnormal angiogenesis and inflammation Anti-VEGF injections do not target inflammation Previously developed by Eisai for hepatic inflammatory indications and by Apexian for solid tumors in

11 Phase 1 and 2 trials Extensively studied in over 20 in-vitro and animal studies with favorable efficacy and safety

16 APX3330: Drug Development History and Patents Significant Preclinical &

Clinical Data Supporting Human Safety, MOA, and PK 12* Phase 1 & Phase 2 Trials Exposure in Humans >10,000 Subject Days at 600mg/day Patents to 2034+ Studied in inflammation/hepatitis & cancer patients (Studied by Eisai

& Apexian, respectively) APX3330 New Chemical Entity Preclinical Efficacy & Toxicology Package APX3330 IND 6 Phase 1 Trials 5 Phase 2 Trials Phase 2 Trials Phase 3 Registration NDA Filing Focus on Ophthalmology * Includes

17 Tao Yan et al. APX3330 Promotes Neurorestorative effects after stroke in

type one diabetic rats. Aging and Disease. Vol 9, Oct 2018 Apurinic/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages. Jedinak A, Dudhgaonkar S, Kelley MR, Sliva D. Anticancer Res. 2011 Feb;31(2):379-85. PMID:

21378315 Fehrenbacher, J. C., Guo, C., Kelley, M. R. & Vasko, M. R. DNA damage mediates changes in neuronal sensitivity induced by the inflammatory mediators, MCP-1 and LPS, and can be reversed by enhancing the DNA repair function of

APE1. Neuroscience 366, 23-35, doi:10.1016/j.neuroscience.2017.09.039 (2017). In-vitro Validation of Mechanism of Action APX3330 Reduces VEGF levels and Inflammatory Cytokines; Provides Neuronal Protection APX3330 reduces pro-inflammatory

cytokines in LPS stimulated macrophages Increasing APX3330 dose VEGF APX3330 reduces VEGF protein expression in preclinical stroke model Control APX3330 APX3330 enhances Ref-1 endonuclease activity in dorsal root ganglion

neurons APX3330 increases DNA oxidative repair and neuronal protection

18 APX3330 VEGF Effects in Normal Cells Abnormal Conditions (e.g.,

hypoxic): Increased level of VEGF activity Normal Conditions: Physiological level of VEGF activity Kamba 2007; Girardi 2010; Li 2014 APX3330 Investigator Brochure Biologic anti-VEGF agents inactivate VEGF directly and reduce VEGF levels

below normal levels Inhibition of Ref-1 by APX3330 returns VEGF levels to normal levels VEGF is a growth factor that is necessary for normal function of multiple cell types including vascular endothelium and neurons By returning VEGF

levels to normal, APX3330 can reduce neovascularization, vascular leakage and the inflammatory response without adverse systemic effects The safety profile of APX3330 to date has not shown any of the adverse effects that has been seen with

systemic administration of anti-VEGF biologics such as cardiovascular pathology, hypertension, arteriothrombotic events, or renal dysfunction APX3330 ARPE-19 cell line APX3330 prevents VEGF overproduction in ARPE-19 cells APX3330 Restores

Normal Levels Unlike Biologic Anti-VEGFs that Reduce VEGF Below Normal

19 APX3330 ZETA-1 Clinical Trial

20 ZETA-1: Phase 2 Trial of Oral AP3330 in Subjects With Diabetic

Retinopathy Multi-center, Randomized, Double-Masked, Placebo-Controlled 24-Week Trial Primary: % subjects with 2 step improvement on DRSS (Diabetic Retinopathy Severity Scale1) at week 24 Secondary: DRSS improvement 1, 2, 3, 4

study eye, fellow eye, binocular DRSS worsening 1, 2, 3, 4, study eye, fellow eye, binocular Progression to vision threatening complications Central subfield thickness (CST) Best Corrected Distance Visual Acuity (BCDVA) DME fellow

eye status Safety and tolerability Exploratory: Inflammatory cytokines Endpoints 25 US sites N = 103 participants with moderately severe to severe NPDR or mild PDR (DRSS 47, 53, 61) Key inclusion: 18 years of age DRSS 47, 53, or

61 Noncentral DME permitted2 ETDRS BCVA 60 letters (20/63) Key exclusion: OCT CST >320 m2 Center involved DME allowed in fellow eye Anti-VEGF within past 6 months3 HbA1c 12.0% Eligibility Criteria 103 subjects enrolled (FPFV

Apr 2021 to LPLV Aug 2022) Topline announced in January 2023 1:1 By Central Reading Center Center-Involved DME in Fellow Eye is Acceptable Includes Systemic or IVT VEGF www.clinicaltrials.gov (NCT04692688); Eylea is registered trademark

of Regeneron NPDR = non-proliferative diabetic retinopathy PDR = proliferative diabetic retinopathy Week 0 Week 12 Week 24 Week 4 Primary Endpoint APX3330 600mg/day (BID) Placebo BID Randomization

21 ZETA-1: Baseline Demographics and Systemic Characteristics Well-Balanced